Communicators
are winners!
News
15.10.2009
Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain
Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain
Nutra Pharma’s Over-the-Counter Treatment for Moderate to Severe Chronic Pain, Cobroxin, is Now Available for Sale Online at Cobroxin.com. The Company Plans to Announce Additional Retail Partnerships as Its Moves Through the Fourth Quarter of 2009 and into the First Quarter of 2010.
PLANTATION, Fla. --Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the availability of Cobroxin online at Cobroxin.com should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contacts
Nutra Pharma Corp.
David Isserman, 877-895-5647
IR@nutrapharma.com
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=US67060U1097
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.
Nutra Pharma’s Over-the-Counter Treatment for Moderate to Severe Chronic Pain, Cobroxin, is Now Available for Sale Online at Cobroxin.com. The Company Plans to Announce Additional Retail Partnerships as Its Moves Through the Fourth Quarter of 2009 and into the First Quarter of 2010.
PLANTATION, Fla. --Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.
Cobroxin is the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting
“We are excited that Cobroxin is now officially available for sale,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Given the significant amount of interest we have received about the product from potential customers, we have initially opted to make Cobroxin available online at Cobroxin.com. We plan to announce our online retail partnerships in the next couple weeks and to continue to update our shareholders about our brick-and-mortar retail partnerships as Cobroxin rolls-out across the United States,” he concluded.
In August, Nutra Pharma announced that it had granted XenaCare Holdings (OTCBB: XCHO) the exclusive license to market and distribute Cobroxin throughout the United States. XenaCare Holdings has planned its initial print marketing campaign for Cobroxin to begin this fall that includes advertising in Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Cobroxin.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the availability of Cobroxin online at Cobroxin.com should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contacts
Nutra Pharma Corp.
David Isserman, 877-895-5647
IR@nutrapharma.com
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=US67060U1097
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.